18f-pf974

Phase 1Radiopharmaceutical

NNational Institute of Mental Health (NIMH)

18f-pf974 is one of 17 therapeutic programs targeting Alzheimer's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alzheimer's DiseaseRecruiting

Alzheimer's DiseasePhase 1

Recruiting

Competition

Competitive Landscape

27 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Phase 3

7 2

Leqembi

Eisai

Phase 3

5 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Qalsody

1 5

Aduhelm

Biogen

Phase 3

4 6

Karx-EC

Bristol-Myers Squibb

Phase 3

2 7

Karxt

Bristol-Myers Squibb

Phase 3

2 8

F-18 FDG

SStanford University

Approved

1 9

Pittsburgh Compound B

MMayo Clinic

Approved

1 10

Avandia

Alnylam Pharmaceuticals

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Alzheimer's Disease

NCT07169630

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Recruiting·NNational Institute of Mental Health (NIMH)·Phase 1·NCT07169630·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 18f-pf974. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 18f-pf974. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical
Highest Phase: Phase 1[1]
Company: NNational Institute of Mental Health (NIMH)

18f-pf974

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News